Top-Thema

07:06 Uhr +0,45%
Australien verhängt Millionenstrafe gegen BMW wegen Kreditgeschäften

Allergan Demonstrates Continued Commitment to Irritable Bowel Syndrome with Diarrhea Management with Two Poster Presentations at ACG 2016

Freitag, 14.10.2016 14:05 von

PR Newswire

DUBLIN, Oct. 14, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to the research and development of new treatments for gastrointestinal diseases, today announced that new data from its irritable bowel syndrome portfolio will be featured in two poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas, NV, October 14-19, 2016. 

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

The scheduled times (noted in local Pacific Time) of the three VIBERZI® (eluxadoline) presentations in the exhibit hall at The Venetian Hotel are as follows:

  • Efficacy and Safety of Eluxadoline in IBS-D Patients Who Report Prior Inadequate Symptom Control with Loperamide
    Date and Time: Monday, October 17, 10:30 AM4:00 PM
    Poster Number: P1123
    Category: Functional Bowel Disease
  • Impact of Baseline Pain Severity on the Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
    Date and Time: Tuesday, October 18, 10:30 AM4:00 PM
    Poster Number: P1876
    Category: Functional Bowel Disease

About VIBERZI

VIBERZI (eluxadoline) is a twice daily, oral medication indicated for use in adults suffering from irritable bowel syndrome with diarrhea (IBS-D).

VIBERZI is an orally active compound indicated for the treatment of IBS-D in men and women that acts locally in the gut.

IMPORTANT SAFETY INFORMATION FOR VIBERZI
Contraindications
VIBERZI is contraindicated for patients with:

  • Known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; structural diseases of the pancreas.
  • Alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages per day.
  • Severe hepatic impairment.
  • A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions
Sphincter of Oddi Spasm:

  • There is a potential for increased risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (e.g., biliary-type pain) with VIBERZI. These events were reported in less than 1% of patients receiving VIBERZI in clinical trials.
  • Patients without a gallbladder are at increased risk. Consider alternative therapies before using VIBERZI in patients without a gallbladder and evaluate the benefits and risks of VIBERZI in these patients.
  • Inform patients without a gallbladder that they may be at increased risk for symptoms of sphincter of Oddi spasm, such as elevated liver transaminases associated with abdominal pain or pancreatitis, especially during the first few weeks of treatment. Instruct patients to stop VIBERZI and seek medical attention if they experience symptoms of sphincter of Oddi spasm.

Pancreatitis:

  • There is a potential for increased risk of pancreatitis not associated with sphincter of Oddi spasm; such events were reported in less than 1% of patients receiving VIBERZI in clinical trials, and the majority were associated with excessive alcohol intake. All pancreatic events resolved upon discontinuation of VIBERZI.
  • Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting, associated with elevations of pancreatic enzymes. Instruct patients to stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis.

Adverse Reactions

  • The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Please also see full Prescribing Information for VIBERZI.
For more information, including full prescribing information about VIBERZI, visit http://www.allergan.com/assets/pdf/viberzi_pi

About IBS-D
Irritable bowel syndrome with diarrhea (IBS-D) is a functional bowel disorder characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 15 million patients in the U.S. Although the exact cause of IBS-D is not known, symptoms are thought to result from a disturbance in the way the gastrointestinal tract and nervous system interact.

IBS-D can be debilitating and there are limited therapeutic options for managing the chronic symptoms. IBS-D is associated with economic burden in direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:   

Investors:


Lisa DeFrancesco


(862) 261-7152




Media: 


Mark Marmur


(862) 261-7558




Fran DeSena


(973) 517-3132

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-demonstrates-continued-commitment-to-irritable-bowel-syndrome-with-diarrhea-management-with-two-poster-presentations-at-acg-2016-300344254.html

SOURCE Allergan plc